etoricoxib 120mg tablets
teva uk ltd - etoricoxib - oral tablet - 120mg
etoricoxib 120mg tablets
de pharmaceuticals - etoricoxib - oral tablet - 120mg
arcoxia
organon (new zealand) limited - etoricoxib 120mg; etoricoxib 120mg - film coated tablet - 120 mg - active: etoricoxib 120mg excipient: calcium hydrogen phosphate carnauba wax croscarmellose sodium magnesium stearate microcrystalline cellulose opadry green 39k11529 purified water active: etoricoxib 120mg excipient: calcium hydrogen phosphate dihydrate carnauba wax croscarmellose sodium magnesium stearate microcrystalline cellulose opadry green 39k11529 purified water - arcoxia is indicated for: · acute and chronic treatment of the signs and symptoms of osteoarthritis (oa) and rheumatoid arthritis (ra) · the management of ankylosing spondylitis (as) · treatment of acute gouty arthritis · relief of acute pain, including pain related to minor dental procedures · relief of chronic musculoskeletal pain the decision to prescribe a selective cox-2 inhibitor should only be made: · if non-pharmacological interventions and simple analgesic therapy i.e.paracetamol have been tried and found to lack analgesic efficacy or to have unacceptable adverse effects in the individual patient; and · after assessment of the individual patient's overall risk factors for developing severe adverse events e.g. history of cardiovascular, renal or gastrointestinal disease.
etoricoxib ab 120 mg film-coat. tabl.
aurobindo sa-nv - etoricoxib 120 mg - film-coated tablet - 120 mg - etoricoxib 120 mg - etoricoxib
etoricoxib eg 120 mg film-coat. tabl.
eg sa-nv - etoricoxib 120 mg - film-coated tablet - 120 mg - etoricoxib 120 mg - etoricoxib
etoricoxib krka 120 mg film-coat. tabl.
krka d.d. novo mesto d.d. - etoricoxib 120 mg - film-coated tablet - 120 mg - etoricoxib 120 mg - etoricoxib
etoricoxib sandoz 120 mg film-coat. tabl.
sandoz sa-nv - etoricoxib 120 mg - film-coated tablet - 120 mg - etoricoxib 120 mg - etoricoxib
cipla etoricoxib etoricoxib 60 mg tablet blister pack
cipla australia pty ltd - etoricoxib, quantity: 60 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin - cipla etoricoxib is indicated for: - symptomatic treatment of the signs and symptoms of osteoarthritis (oa). - treatment of acute gouty arthritis. - treatment of acute pain, including that related to primary dysmenorrhea and minor dental procedures. the decision to prescribe a selective cox-2 inhibitor should be based on an assessment of the individual patient's overall risks.
cipla etoricoxib etoricoxib 30 mg tablet blister pack
cipla australia pty ltd - etoricoxib, quantity: 30 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cipla etoricoxib is indicated for: - symptomatic treatment of the signs and symptoms of osteoarthritis (oa). - treatment of acute gouty arthritis. - treatment of acute pain, including that related to primary dysmenorrhea and minor dental procedures. the decision to prescribe a selective cox-2 inhibitor should be based on an assessment of the individual patient's overall risks.
cipla etoricoxib etoricoxib 120 mg tablet blister pack
cipla australia pty ltd - etoricoxib, quantity: 120 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cipla etoricoxib is indicated for: - symptomatic treatment of the signs and symptoms of osteoarthritis (oa). - treatment of acute gouty arthritis. - treatment of acute pain, including that related to primary dysmenorrhea and minor dental procedures. the decision to prescribe a selective cox-2 inhibitor should be based on an assessment of the individual patient's overall risks.